PharMerica Co. (NYSE:PMC) – Research analysts at KeyCorp lifted their FY2017 earnings estimates for shares of PharMerica in a research report issued on Monday. KeyCorp analyst J. Gurda now anticipates that the company will post earnings of $1.90 per share for the year, up from their previous estimate of $1.85. KeyCorp also issued estimates for PharMerica’s FY2018 earnings at $2.05 EPS.

Separately, Zacks Investment Research cut PharMerica from a “hold” rating to a “sell” rating in a report on Tuesday, February 28th.

Earnings History and Estimates for PharMerica (NYSE:PMC)

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/05/19/fy2017-earnings-estimate-for-pharmerica-co-pmc-issued-by-keycorp.html.

Shares of PharMerica (NYSE:PMC) opened at 24.85 on Wednesday. PharMerica has a 12 month low of $19.20 and a 12 month high of $28.72. The company has a 50 day moving average of $23.66 and a 200-day moving average of $24.32. The firm has a market capitalization of $765.11 million, a P/E ratio of 36.01 and a beta of 1.10.

PharMerica (NYSE:PMC) last announced its quarterly earnings results on Wednesday, May 10th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.02. The business had revenue of $566.80 million for the quarter, compared to the consensus estimate of $536.85 million. PharMerica had a net margin of 1.64% and a return on equity of 10.40%. PharMerica’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period last year, the company posted $0.45 EPS.

Institutional investors have recently bought and sold shares of the company. Alambic Investment Management L.P. boosted its position in PharMerica by 71.9% in the third quarter. Alambic Investment Management L.P. now owns 15,300 shares of the company’s stock worth $429,000 after buying an additional 6,400 shares during the last quarter. Staley Capital Advisers Inc. boosted its position in PharMerica by 35.4% in the third quarter. Staley Capital Advisers Inc. now owns 19,586 shares of the company’s stock worth $550,000 after buying an additional 5,121 shares during the last quarter. BlackRock Fund Advisors boosted its position in PharMerica by 6.7% in the third quarter. BlackRock Fund Advisors now owns 2,347,889 shares of the company’s stock worth $65,905,000 after buying an additional 147,793 shares during the last quarter. Rhumbline Advisers boosted its position in PharMerica by 10.8% in the third quarter. Rhumbline Advisers now owns 57,796 shares of the company’s stock worth $1,622,000 after buying an additional 5,622 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in PharMerica during the third quarter worth about $488,000. Hedge funds and other institutional investors own 97.15% of the company’s stock.

About PharMerica

5 Day Chart for NYSE:PMC

Receive News & Stock Ratings for PharMerica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co. and related stocks with our FREE daily email newsletter.